The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer.
Claudio Zamagni
No relevant relationships to disclose
Myriam Perrone
No relevant relationships to disclose
Vincenzo Dario Mandato
No relevant relationships to disclose
Alessandra Bologna
No relevant relationships to disclose
Daniela Rubino
No relevant relationships to disclose
Giorgia Zucchini
No relevant relationships to disclose
Nuria Maria Asensio Sierra
No relevant relationships to disclose
Elena Barbieri
No relevant relationships to disclose
Marta Cubelli
No relevant relationships to disclose
Pierandrea De Iaco
No relevant relationships to disclose
Martino Abrate
No relevant relationships to disclose